Semaglutide (Ozempic® / Wegovy®) is FDA-approved for chronic weight management. Weekly injection, clinically proven.
Average weight loss in clinical trials over 68 weeks. Individual results vary based on starting weight, lifestyle, and adherence.
One injection per week in-office at Aviva or self-administered at home at no extra charge.
Semaglutide is included in the Aviva 3-month weight loss program alongside 12 EvolveX sessions and 3 Morpheus8 treatments.
Semaglutide (Ozempic® / Wegovy®) is FDA-approved for chronic weight management. Weekly injection, clinically proven.
Average weight loss in clinical trials over 68 weeks. Individual results vary based on starting weight, lifestyle, and adherence.
One injection per week in-office at Aviva or self-administered at home at no extra charge.
Semaglutide is included in the Aviva 3-month weight loss program alongside 12 EvolveX sessions and 3 Morpheus8 treatments.
GLP-1 RECEPTOR SIGNALING — HUNGER REGULATION
Semaglutide activates GLP-1 receptors in the brain's appetite-regulating centers, reducing hunger signals and increasing the sensation of fullness after smaller meals. Most patients report a significant reduction in food noise the constant background preoccupation with food within the first few weeks of treatment.
Appetite reduction typically felt within weeks 1–4 of starting treatment
BLOOD SUGAR REGULATION + INSULIN SENSITIVITY
Semaglutide improves insulin secretion in response to meals and reduces glucagon release improving blood sugar control and insulin sensitivity. This is particularly beneficial for pre-diabetic patients and those with type 2 diabetes, but the metabolic improvements contribute to weight loss outcomes for all patients.
Metabolic changes measurable within 4–8 weeks of consistent use
PROGRESSIVE + LONG-TERM RESULTS
Unlike crash diets that produce rapid loss followed by rebound, semaglutide works by changing the underlying appetite signals that make sustained weight loss difficult. Patients lose weight progressively, and the clinical data shows continued loss throughout the 68-week trial period not a plateau after the first few months.
15% average body weight loss over 68 weeks in clinical trials (Wegovy® STEP program)
GLP-1 receptor agonist single mechanism
15% average body weight loss in clinical trials (STEP program)
Well-established safety profile since 2017 (Ozempic) and 2021 (Wegovy)
Once-weekly injection same dosing schedule
Longer track record more real-world patient data available
Good choice for patients who prefer the most established option
Dual GLP-1 + GIP receptor agonist two mechanisms simultaneously
Up to ~22% average body weight loss in clinical trials (SURMOUNT program)
Newer approved for weight management (Zepbound) in 2023
Once-weekly injection same dosing schedule
Superior average clinical results the newer generation option
Good choice for patients who want the highest average clinical outcome
EvolveX RF and EMS body contouring runs in parallel with your semaglutide program 4 sessions per month. As fat reduces, EvolveX tightens the overlying skin and stimulates muscle tone. Included in the program.
Morpheus8 RF microneedling addresses abdominal, arm, or facial skin laxity that develops alongside significant weight loss. One session per month across the program. Applied to body or face based on your needs.
Significant GLP-1 weight loss can accelerate facial volume loss. Sculptra collagen biostimulation rebuilds structural support gradually and naturally available as a complementary treatment during or after your program.
Clinical trials for Wegovy® (the weight-management formulation of semaglutide) show an average body weight loss of approximately 15% over 68 weeks. Individual results vary significantly based on starting weight, diet, activity level, and program adherence. Your Aviva provider will set a realistic, personalized expectation at your free consultation.
Both are GLP-1 medications available at Aviva. Tirzepatide (Mounjaro) is a newer dual-agonist that activates both GLP-1 and GIP receptors simultaneously and shows higher average weight loss in clinical trials up to ~22% vs. ~15% for semaglutide. Semaglutide has a longer track record. Your provider will recommend the right option based on your medical history and goals.
Semaglutide has been in clinical use since 2017 (Ozempic) and was approved for weight management (Wegovy) in 2021. It has an extensive safety and real-world efficacy record. Common side effects nausea, constipation, fatigue are most pronounced during dose titration and typically improve as your body adjusts. Your Aviva provider reviews contraindications and your full medical history before prescribing.
Yes. Semaglutide is delivered in a pre-filled pen for once-weekly subcutaneous injection. Aviva offers in-office injection administration at no extra charge, or you can self-administer at home after a brief technique demonstration. Most patients transition to home self-administration after the first session.
Weight regain after stopping GLP-1 medications without a transition plan is well-documented. At Aviva, your provider discusses a transition strategy before you reach the end of your program including dose reduction protocols, peptide therapy as ongoing metabolic support, and lifestyle maintenance. The goal is not just the 3-month result but a sustainable outcome.
Start with a free consultation. Your Aviva provider reviews your health history, confirms candidacy, recommends semaglutide or tirzepatide, and walks you through the full program including EvolveX and Morpheus8 session scheduling. Enrolling through the free consultation saves you an additional $100 on program enrollment.
Anyone can send you a prescription. At Aviva Medical Spa in Miami’s Design District, your semaglutide program is managed by a licensed medical provider who knows your health history, monitors your response, and adjusts your dosing based on how you’re actually doing not a protocol built for the average patient. You also have direct access to a team that understands the aesthetic changes that come with significant weight loss and can address them as part of the same program. This is not a telehealth subscription. It’s a supervised medical program with a real provider and a plan for the whole transformation.
Your Glow Starts Here
Your Glow Starts Here
